Drug Type Biosimilar, Monoclonal antibody |
Synonyms Bevacizumab Biosimilar (Hualan Genetic Engineering Co., Ltd.), 贝伐珠单抗生物类似药(Hualan Genetic Engineering Co., Ltd.), 重组抗血管内皮生长因子(VEGF)单抗(华兰基因工程) + [2] |
Target |
Action inhibitors |
Mechanism VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors), Angiogenesis inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date China (15 Nov 2024), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Fallopian Tube Carcinoma | China | 15 Nov 2024 | |
Hepatocellular Carcinoma | China | 15 Nov 2024 | |
Metastatic Colorectal Carcinoma | China | 15 Nov 2024 | |
Non-Small Cell Lung Cancer | China | 15 Nov 2024 | |
Ovarian Epithelial Carcinoma | China | 15 Nov 2024 | |
Primary peritoneal carcinoma | China | 15 Nov 2024 | |
Recurrent Glioblastoma | China | 15 Nov 2024 | |
Uterine Cervical Cancer | China | 15 Nov 2024 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-squamous non-small cell lung cancer | Phase 3 | China | 28 Jun 2019 |